VOR - NASDAQ
Vor Biopharma Inc.
$13.44
-0.037%Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotNo Revenue Data
VOR has not reported any revenue values in the available annual periods.
Vor Biopharma Inc. Profit Bridge
Profitability Analysis
Vor Biopharma Inc. Income Statement
VOR • NASDAQ
| Vor Biopharma Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
GROSS PROFIT | ||||||||
(0.0) | (0.0) | (3.5M) | (9M) | (0.0) | (0.0) | (91K) | (20K) | |
0.0 | 0.0 | -3.5M | -9M | 0.0 | 0.0 | -91K | -20K | |
OPERATING INCOME | ||||||||
(371.6M) | (121.2M) | (122.5M) | (84.5M) | (69M) | (43.4M) | (10.4M) | (2.9M) | |
(50.1M) | (27.9M) | (31.7M) | (19.9M) | (21.5M) | (11.7M) | (4.2M) | (427K) | |
(321.5M) | (93.3M) | (94.3M) | (64.6M) | (47.5M) | (31.6M) | (6.2M) | (2.4M) | |
-371.6M | -121.2M | -126M | -93.4M | -69M | -43.4M | -10.4M | -2.9M | |
PRE-TAX INCOME | ||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (608K) | (1M) | |
5.9M | 4.3M | 8.2M | 1.3M | 119K | 29K | -454K | 0.0 | |
(0.0) | (0.0) | -3.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-324.3M | 4.3M | 8.2M | 1.3M | 119K | 29K | -422K | -1.3M | |
-696M | -116.9M | -117.9M | -92.1M | -68.9M | -43.3M | -10.8M | -4.2M | |
NET INCOME | ||||||||
-696M | -116.9M | -117.9M | -92.1M | -68.9M | -43.3M | -11.4M | -4.2M |
SEC Filings
VOR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
S-3 S-3 N/A | April 27, 2026 | April 27, 2026 | ||
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 26, 2026 | 2026 | |
S-3 S-3 N/A | January 29, 2026 | January 29, 2026 | ||
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 05, 2025 | 2025 |
Related Guides
Continue your VOR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.